Merck KGaA Teams With Saturnus Bio to Build Precision Cardiology Portfolio for Rare Genetic Cardiomyopathies
Merck KGaA, Darmstadt, Germany has entered a strategic research-stage collaboration with Saturnus Bio, a biotechnology company founded by Versant Ventures, in a move aimed at establishing a new foothold in the emerging field of rare genetic cardiomyopathies. The partnership marks an early but potentially significant step in Merck KGaA’s effort to expand into precision cardiology and develop targeted therapies for patients with inherited heart muscle disorders that currently have few, if any, disease-modifying treatment options.
The companies said the collaboration is designed to create a foundational portfolio focused on rare monogenic cardiomyopathies, a group of serious cardiovascular disorders caused by mutations in a single gene. These conditions can lead to progressive cardiac dysfunction, heart failure, arrhythmias, sudden cardiac death, and substantial long-term morbidity, yet the therapeutic landscape remains limited. By combining Saturnus Bio’s research platform with Merck KGaA’s drug development capabilities and interest in precision medicine, the two companies hope to accelerate the development of new therapies tailored to the specific genetic drivers of disease.
The deal also reflects a broader industry trend in which large pharmaceutical companies are increasingly turning to focused biotech startups and venture-backed innovation models to access cutting-edge science in specialized therapeutic areas. In this case, Merck KGaA is pairing with a newly launched company built around precision cardiology, a field that seeks to match targeted treatments to clearly defined molecular and genetic disease mechanisms rather than treating heart disease as a broad, undifferentiated category.
A new bet on precision cardiology and rare cardiovascular disease
Merck KGaA described the collaboration as part of its strategy to address significant unmet medical needs in rare patient populations through highly targeted therapeutic approaches. Rare genetic cardiomyopathies are an especially challenging area because many of these diseases are severe, progressive, and underdiagnosed, yet they often lack approved treatments that directly address the underlying genetic defect.
Instead, current care for patients with inherited cardiomyopathies frequently centers on symptom management, monitoring of disease progression, arrhythmia prevention, and advanced interventions such as implantable cardiac devices or heart transplantation in the most severe cases. That leaves a major opportunity for therapies that can intervene earlier in the disease process and potentially modify the biology driving cardiac deterioration.
David Weinreich, Merck KGaA’s Head of Research and Development and Chief Medical Officer, said the company sees the partnership as a way to speed the development of innovative therapies for genetic cardiomyopathies through a precision cardiology approach. He said Merck intends to leverage Saturnus Bio’s scientific expertise and research capabilities while building on its own technology base, including its armed antibody capabilities, to explore new ways of delivering targeted treatments to patients affected by these rare conditions.
His comments suggest that Merck KGaA is not approaching this collaboration as a standalone niche research project, but rather as an entry point into a broader cardiovascular strategy centered on genetically defined disease. The company indicated that genetic cardiomyopathies represent an important initial opportunity for its cardiovascular business, especially because the field remains underserved and lacks approved therapies that specifically target the genetic drivers of disease.
Saturnus Bio launched with Merck partnership as part of Versant model
For Saturnus Bio, the agreement effectively provides both a strategic launchpad and a major financial backer. The company was founded by Versant Ventures and is being built around the goal of developing first-in-class medicines for genetic cardiomyopathies. Saturnus is led by Rick Dewey, MD, an entrepreneur-in-residence at Versant Ventures who also serves as the company’s chief executive officer.
Dewey said the launch of Saturnus through a foundational partnership with Merck KGaA reflects Versant’s model of working with pharmaceutical companies to create new biotech ventures in areas of high unmet need. In this case, the company is starting life with a focused mission in precision cardiology and with a partner already committed to supporting early research and development.
That structure is increasingly common in biotech venture creation, where investors such as Versant establish new companies around promising scientific concepts and secure strategic pharmaceutical involvement early in the process. The approach can provide emerging biotechs with non-dilutive funding, scientific validation, and a clearer path to downstream acquisition or licensing, while giving pharma companies earlier access to innovation in areas they want to build.
According to Dewey, Saturnus is positioned to accelerate a pipeline of therapies aimed at rare genetic cardiomyopathies. Although the companies have not disclosed specific disease targets or drug candidates, the emphasis on targeted gene modulation suggests that the platform may be designed to intervene at the level of disease-causing genetic or molecular pathways rather than treating symptoms downstream.
Deal includes $50 million upfront and a build-to-buy structure
Financially, the collaboration is structured as a research-stage build-to-buy agreement, a deal model that has become increasingly popular in the pharmaceutical industry for early innovation partnerships. Under the terms announced by the companies, Merck KGaA will provide $50 million upfront to support Saturnus Bio’s research activities. In return, the company will receive a minority equity stake in Saturnus, aligning Merck financially with the biotech’s progress while giving it a direct role in supporting early development.
The deal also includes additional success-based preclinical milestone payments, which would provide Saturnus with further funding as programs advance through early research and development. Most notably, Merck KGaA has secured exclusive rights to acquire Saturnus Bio in the future through a pre-agreed option structure. If Merck chooses to exercise that option, the acquisition would involve a predetermined option payment plus additional success-based earnouts tied to the performance of the programs.
This type of structure offers advantages for both sides. For Merck KGaA, it provides early access to a potentially valuable innovation platform while limiting upfront risk compared with a full acquisition at launch. The company can fund and help shape the science, observe how the pipeline develops, and decide later whether the assets warrant full integration. For Saturnus and Versant, the model offers meaningful capital support and a built-in strategic path forward while still allowing the company to operate independently during the early research phase.
Focus on targeted gene modulation in monogenic heart disease
At the scientific level, the partnership is centered on next-generation precision cardiology using targeted gene modulation to treat rare monogenic cardiomyopathies. These disorders arise from pathogenic variants in a single gene and often present with severe clinical consequences, including thickening or weakening of the heart muscle, impaired pumping function, dangerous arrhythmias, and progressive heart failure.
Because the root cause is genetic, these diseases may be particularly well suited to precision medicine strategies that intervene upstream in the disease mechanism. Instead of broadly treating heart failure symptoms or electrical complications, targeted therapies could potentially address the abnormal molecular signaling or protein dysfunction triggered by the underlying mutation.
That scientific rationale is one reason genetic cardiomyopathies are drawing more attention from biotech and pharmaceutical developers. Although the patient populations are relatively small, the biological targets can be well defined, and successful therapies may offer the possibility of disease modification in areas where standard cardiovascular drugs are often insufficient.
For Merck KGaA, the collaboration offers a way to enter that space through a research partnership rather than building the capability entirely in-house. The company said the collaboration will augment its efforts in precision medicine-defined indications, reinforcing a strategy that emphasizes not just broad therapeutic areas, but subpopulations and diseases that can be better understood—and potentially de-risked—through genetics, translational biology and early clinical testing.
Part of a broader R&D productivity strategy
Merck KGaA also framed the Saturnus Bio partnership within its wider effort to improve research productivity and expand the output of its pipeline in a sustainable way. The company said it remains committed to leveraging advanced technologies and data science to accelerate the discovery and delivery of breakthrough medicines. In that context, rare genetic cardiomyopathies may represent an attractive target area because they combine high unmet need with the possibility of clearer biological validation than many broader cardiovascular indications.
The company’s stated strategy is to focus on indications that can be de-risked through robust preclinical and early clinical testing, thereby increasing the likelihood that promising candidates can move efficiently through development and ultimately reach patients. Rare genetically defined diseases often fit that framework because they may offer more precise biomarkers, more direct mechanistic hypotheses, and clearer patient segmentation than large heterogeneous disease populations.
By partnering with Saturnus at the research stage, Merck KGaA is effectively placing an early strategic bet on that model in cardiovascular medicine. Rather than waiting for later-stage clinical validation, it is moving upstream into venture-backed innovation with the option to acquire the company if the science progresses as hoped.
Building a foothold in an underserved field
The collaboration with Saturnus Bio is still at an early stage, and many details about the scientific programs remain undisclosed. Still, the partnership is notable because it signals Merck KGaA’s intention to build a presence in rare inherited cardiovascular disease, an area that has historically received less drug development attention than oncology, immunology or metabolic disease despite the severity of the conditions involved.
For Saturnus Bio, the deal provides both financial backing and a high-profile strategic partner as it works to establish itself in precision cardiology. For Merck KGaA, it offers a structured way to enter a promising but high-risk field through a combination of upfront funding, equity participation and a future acquisition option.
If the collaboration succeeds, it could help lay the groundwork for a new portfolio of therapies aimed at rare genetic cardiomyopathies—an area where patients today still face limited options and where targeted treatments could meaningfully change the course of disease. For now, the alliance represents an early but significant move in Merck KGaA’s effort to bring precision medicine deeper into cardiovascular disease and rare genetic disorders.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck KGaA, Darmstadt, Germany, generated sales of € 21.1 billion in 65 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
